关键护理结果中的种族差异来源:单一中心分析分析
Journal of health care for the poor and underserved
|August 18, 2025
概括
在重症监护室 (ICU) 存在种族差异,包括死亡率和停留时间. 社会经济因素和顺序性器官衰竭评估 (SOFA) 评分解释了大多数差距,社会经济因素令人惊地弥补了一些死亡率差异.
科学领域:
- 关键护理医学 关键护理医学
- 医疗服务研究 医疗服务研究
- 卫生公平性健康公平性
背景情况:
- 关于健康结果的种族和民族差异已经得到了充分的证据.
- 关于重症监护结果的研究正在增长.
- 了解重症监护室 (ICU) 的差异对于改善患者护理至关重要.
研究的目的:
- 在一个城市重症监护病房 (ICU) 中量化种族差异的来源.
- 检查单位内死亡率和ICU停留时间的差异.
- 确定社会经济和生理因素在多大程度上解释了这些差异.
主要方法:
- 在2014年至2021年期间,从城市ICU分析患者数据.
- 使用邮政编码和社会人口统计信息.
- 量化社会经济因素和顺序器官衰竭评估 (SOFA) 评分对观察到的差异的贡献.
主要成果:
- 在种族/族裔少数群体和白人患者之间观察到单位内死亡率和ICU停留时间的显著差异.
- 社会经济因素和SOFA分数解释了黑人-白人,西班牙裔-白人和亚裔-白人停留时间的差距.
- SOFA评分完全解释了黑人-白人死亡率差距,而社会经济因素意外地弥补了这些差异.
结论:
- 社会经济地位和生理因素 (SOFA分数) 是ICU结果种族差异的关键决定因素.
- 这些因素的复杂相互作用凸显了针对性干预的必要性,以解决重症监护中的健康不平等问题.
- 需要进一步的研究来了解社会经济因素背后的机制,以弥补死亡率差距.
更多相关视频
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
14.6K
10:38Observational Study Protocol for Repeated Clinical Examination and Critical Care Ultrasonography Within the Simple Intensive Care Studies
Published on: January 16, 2019
20.4K
相关概念视频
Bias in Epidemiological Studies
675
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
675
Comparing the Survival Analysis of Two or More Groups
285
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
285
Relative Risk
342
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
342
Ethical Issues
1.2K
Nurses are essential in patient care, upholding the ethical principles of their profession and effectively navigating ethical dilemmas. Neglecting ethical issues can lead to inadequate patient care, compromised therapeutic relationships, and moral distress among healthcare workers.
Ethical Concerns in Healthcare:
Ethical Concerns in Healthcare:
1.2K
Cancer Survival Analysis
453
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
453
Hazard Ratio
243
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
243
